Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Hepatitis C in 2012

On the fast track towards IFN-free therapy for hepatitis C?

Nature Reviews Gastroenterology & Hepatology volume 10, pages 76–78 (2013)Cite this article

Subjects

With the first HCV protease inhibitors approved in 2011, we are currently in a transition phase towards a shift in treatment paradigm. Within the next 3 years, the vast majority of patients with hepatitis C will probably be treated with completely different drugs in most Western countries.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: IFN-free combination therapies of direct-acting antivirals against hepatitis C that are currently under investigation (including previously tested IFN-free combinations).

References

  1. Dusheiko, G. & Wedemeyer, H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 61, 1647–1652 (2012).

    Article  CAS  Google Scholar 

  2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 55, 245–264 (2011).

  3. Manns, M. P., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350–1359 (2006).

    Article  CAS  Google Scholar 

  4. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216–224 (2012).

    Article  CAS  Google Scholar 

  5. Chayama, K. et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55, 742–748 (2012).

    Article  CAS  Google Scholar 

  6. Zeuzem, S. et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55, 749–758 (2012).

    Article  CAS  Google Scholar 

  7. Furusyo, N. et al. Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial. J. Hepatol. 57, 1186–1192 (2012).

    Article  CAS  Google Scholar 

  8. Murakami, Y. et al. Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle. Microbes Infect. http://dx.doi.org/10.1016/j.micinf.2012.10.003.

  9. Cammà, C. et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 56, 850–860 (2012).

    Article  Google Scholar 

Download references

Acknowledgements

The author would like to acknowledge the support of a grant from the German Center for Infectious Diseases (DZIF). The author thanks Drs Benjamin Maasoumy and Svenja Hardtke for editorial assistance.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Street, Hannover, 30625, Germany

    Heiner Wedemeyer

Authors
  1. Heiner Wedemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

H. Wedemeyer has received research grant and/or honoraria for consulting or speaking from Abbott, Biolex, BMS, Gilead, ITS, JJ/Janssen-Cilag, Merck/Schering-Plough, Novartis, Roche, Roche Diagnostics, Siemens, Transgene and ViiV.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wedemeyer, H. On the fast track towards IFN-free therapy for hepatitis C?. Nat Rev Gastroenterol Hepatol 10, 76–78 (2013). https://doi.org/10.1038/nrgastro.2012.247

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2012.247

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing